title: Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
abstract: Drug resistance is an important cause of antiretroviral therapy failure in human immunodeficiency virus (HIV)-infected patients. Mutations in the protease render the virus resistant to protease inhibitors (PIs). Gag cleavage sites also mutate, sometimes correlating with resistance mutations in the protease, but their contribution to resistance has not been systematically analyzed. The present study examines mutations in Gag cleavage sites that associate with protease mutations and the impact of these associations on drug susceptibilities. Significant associations were observed between mutations in the nucleocapsid-p1 (NC-p1) and p1-p6 cleavage sites and various PI resistance-associated mutations in the protease. Several patterns were frequently observed, including mutations in the NC-p1 cleavage site in combination with I50L, V82A, and I84V within the protease and mutations within the p1-p6 cleavage site in combination with D30N, I50V, and I84V within the protease. For most patterns, viruses with mutations both in the protease and in either cleavage site were significantly less susceptible to specific PIs than viruses with mutations in the protease alone. Altered PI resistance in HIV-1 was found to be associated with the presence of Gag cleavage site mutations. These studies suggest that associated cleavage site mutations may contribute to PI susceptibility in highly specific ways depending on the particular combinations of mutations and inhibitors. Thus, cleavage site mutations should be considered when assessing the level of PI resistance.
authors.affiliation: Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605, USA.
authors.forename: Madhavi
authors.initials: M
authors.lastname: Kolli
authors.forename: Eric
authors.initials: E
authors.lastname: Stawiski
authors.forename: Colombe
authors.initials: C
authors.lastname: Chappey
authors.forename: Celia A
authors.initials: CA
authors.lastname: Schiffer
mesh_terms: D000595:Amino Acid Sequence; D001665:Binding Sites; D024882:Drug Resistance, Viral / Q000502:physiology*; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D020815:Polyproteins / Q000235:genetics / Q000378:metabolism; D011487:Protein Conformation; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
chemical_list: D017320:HIV Protease Inhibitors; D020815:Polyproteins; D054301:gag Gene Products, Human Immunodeficiency Virus; D016333:HIV Protease
references.citation: J Virol. 1998 Sep;72(9):7632-7
references.pmid: 9696866
references.citation: J Virol. 1995 Sep;69(9):5228-35
references.pmid: 7636964
references.citation: Eur J Biochem. 2002 Aug;269(16):4114-20
references.pmid: 12180988
references.citation: N Engl J Med. 2001 Feb 15;344(7):472-80
references.pmid: 11172188
references.citation: Eur J Biochem. 1999 Jul;263(1):238-45
references.pmid: 10429209
references.citation: J Virol. 2002 Feb;76(4):1753-61
references.pmid: 11799170
references.citation: Virology. 2008 Sep 1;378(2):272-81
references.pmid: 18599104
references.citation: J Virol. 1997 Aug;71(8):5723-32
references.pmid: 9223458
references.citation: J Clin Virol. 2008 Aug;42(4):405-8
references.pmid: 18472298
references.citation: Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5597-601
references.pmid: 8202533
references.citation: PLoS Med. 2007 Jan;4(1):e36
references.pmid: 17227139
references.citation: Antimicrob Agents Chemother. 2004 Feb;48(2):437-43
references.pmid: 14742192
references.citation: Structure. 2002 Mar;10(3):369-81
references.pmid: 12005435
references.citation: Ann Pharmacother. 1999 Mar;33(3):325-39
references.pmid: 10200859
references.citation: AIDS. 2007 May 31;21(9):1210-3
references.pmid: 17502734
references.citation: J Virol. 2002 Aug;76(15):7398-406
references.pmid: 12097552
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32
references.pmid: 16127059
references.citation: J Virol. 1997 Sep;71(9):6662-70
references.pmid: 9261388
references.citation: AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1209-13
references.pmid: 10957718
references.citation: J Virol. 2006 Apr;80(7):3607-16
references.pmid: 16537628
references.citation: Antimicrob Agents Chemother. 1998 Oct;42(10):2637-44
references.pmid: 9756769
references.citation: Antimicrob Agents Chemother. 1998 Nov;42(11):2775-83
references.pmid: 9797203
references.citation: J Virol. 1997 Feb;71(2):1089-96
references.pmid: 8995629
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):920-8
references.pmid: 10722492
references.citation: J Virol. 2004 Nov;78(22):12446-54
references.pmid: 15507631
references.citation: Biochemistry. 1995 Jul 25;34(29):9282-7
references.pmid: 7626598
references.citation: AIDS. 1999 Dec 3;13(17):2349-59
references.pmid: 10597776
references.citation: Chem Biol. 2004 Oct;11(10):1333-8
references.pmid: 15489160
references.citation: J Infect Dis. 2004 May 15;189(10):1802-10
references.pmid: 15122516
references.citation: Adv Exp Med Biol. 1998;436:75-83
references.pmid: 9561202
references.citation: Virology. 2006 Apr 10;347(2):405-9
references.pmid: 16430939
references.citation: Antimicrob Agents Chemother. 2002 Apr;46(4):1086-92
references.pmid: 11897594
references.citation: PLoS Pathog. 2009 Mar;5(3):e1000345
references.pmid: 19300491
references.citation: AIDS Res Hum Retroviruses. 2006 Dec;22(12):1300-5
references.pmid: 17209774
references.citation: J Virol. 1996 Jun;70(6):3763-9
references.pmid: 8648711
references.citation: Nucleic Acids Res. 2003 Jan 1;31(1):298-303
references.pmid: 12520007
references.citation: Antiviral Res. 1998 Jul;39(1):1-23
references.pmid: 9754946